Oncology Nurses Quality Improvement Series

Please note that this program was recorded before FDA-approval for expanded indications were received for Cemiplimab (2/22/21) and Pembrolizumab (3/23/21).

Cemiplimab is now approved for use as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) (locally advanced who are not candidates for surgical resection or definitive chemo-radiation or metastatic) whose tumors have high PD-L1 expression (TPS ≥ 50%) without EGFR, ALK or ROS1 aberrations. This approval was based on data from Study 1624, which together demonstrated significant improvements in OS and PFS for patients receiving cemiplimab compared to those treated with platinum-based chemotherapy.

Pembrolizumab is now approved for use in patients with esophageal or gastroesophogeal (GEJ) carcinoma (metastatic or locally advanced who are not candidates for surgical resection or definitive chemo-radiation) in combination with platinum and fluoropyrimidine-based chemotherapy. This approval was based on data from KEYNOTE-590, which demonstrated significant improvements in OS and PFS for patients receiving pembrolizumab with chemotherapy compared to those treated with chemotherapy alone.

PRESENTATION TRACKS

Immune Checkpoint inhibitors: The Oncology Nurse’s Role in the Monitoring and Early Intervention of Immune-related Adverse Events

FACULTY

Arjun V. Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

Updates for Oncology Nurses—Optimizing the Paradigm Shift Driven by CKD 4/6 Inhibitors in Metastatic HR-Positive, HER2-Negative Breast Cancer

FACULTY

Sramila Aithal, MD
Director and Lead, Breast Center of Advanced Oncology
Medical Oncologist and Hematologist
Cancer Treatment Centers of America
Philadelphia, PA

PROGRAM OVERVIEW

This case-based online activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy, as well as, the treatment and management of patients with HER2-negative breast cancer.


TARGET AUDIENCE

This initiative is designed to meet the educational needs of oncology nurses involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy. Also, this initiative is designed to meet the educational needs of oncology nurses, medical oncologists, pharmacists, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.


LEARNING OBJECTIVES – irAEs

Upon completion of the program, attendees should be able to:

  • Review the mechanism of action and clinical profiles of available and emerging immunotherapies used alone or in combination across lines of therapy in multiple tumor types
  • Describe the side effects and toxicities associated with available immunotherapeutic options for the treatment of patients with various types of cancer and strategies to manage them in clinical practice
  • Summarize best practices for the use of biomarker testing in clinical practice to guide treatment making decisions regarding cancer immunotherapies including the potential for response to therapy and the occurrence of irAEs
  • Discuss current recommendations and emerging evidence regarding the use of immunotherapies for patients with cancer during the COVID-19 pandemic including the management of irAEs and the utility of telemedicine
  • Describe the fundamentals of patient-centered SDM approaches and their utility in optimizing patient care in clinical practice

LEARNING OBJECTIVES – HER2-Negative

Upon completion of the program, attendees should be able to:

  • Identify the patient who will benefit from CDK 4/6 inhibitor therapy with consideration of patient and disease characteristics and appropriately time its use in the course of the disease
  • Recognize commonly associated toxicities of CDK4/6 inhibition, and apply strategies for both the monitoring and management of adverse events associated with their use in patients with metastatic breast cancer
  • Utilize methodologies to activate all members of the healthcare team, encourage collaboration, and incorporate shared-decision-making and survivorship tools to assist in optimizing patient outcomes and management of adverse events
  • Review the various roles for oncology nurses in the management of patients with breast cancer

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 2.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy and/or hormone receptor-positive, HER2-negative metastatic breast cancer.
CNE Credits: 2.0 ANCC Contact Hours.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.0 contact hours of continuing nursing education for RNs and APNs.


ONCC STATEMENT

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Arjun V. Balar, MD, has received consultant fees from Merck, Genentech, AstraZeneca, Pfizer, and Seattle Genetics; and received fees for non-CME/CE services received directly from a commercial interest or its agent from Merck, Genentech, and AstraZeneca.

Sramila Aithal, MD is a Speakers’ Bureau member for Pfizer, Novartis, Seattle Genetics and Puma. She was a principal investigator for pharmaceutical initiated clinical trials at CTCA.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.



The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the posttest and online evaluation form.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

RELEASE DATE: November 17, 2020

EXPIRATION DATE: November 17, 2021

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.